Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Deferred Tax (2018 - 2024)

Eton Pharmaceuticals' Long-Term Deferred Tax history spans 5 years, with the latest figure at $404000.0 for Q4 2024.

  • On a quarterly basis, Long-Term Deferred Tax rose 139.05% to $404000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $404000.0, a 139.05% increase, with the full-year FY2024 number at $404000.0, up 139.05% from a year prior.
  • Long-Term Deferred Tax hit $404000.0 in Q4 2024 for Eton Pharmaceuticals, up from $169000.0 in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for ETON hit a ceiling of $18.5 million in Q4 2021 and a floor of $169000.0 in Q4 2023.
  • Historically, Long-Term Deferred Tax has averaged $6.4 million across 3 years, with a median of $404000.0 in 2024.
  • The widest YoY moves for Long-Term Deferred Tax: up 139.05% in 2024, down 139.05% in 2024.
  • Tracing ETON's Long-Term Deferred Tax over 3 years: stood at $18.5 million in 2021, then tumbled by 99.09% to $169000.0 in 2023, then skyrocketed by 139.05% to $404000.0 in 2024.
  • Business Quant data shows Long-Term Deferred Tax for ETON at $404000.0 in Q4 2024, $169000.0 in Q4 2023, and $18.5 million in Q4 2021.